The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

OBJECTIVE: To explore the population health impact of treating all US adults eligible for the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) with icosapent ethyl (IPE), we estimated (1) the number of ASCVD events and healthcare costs that could be prevented; a...

Descripción completa

Detalles Bibliográficos
Autores principales: Derington, Catherine G., Bress, Adam P., Herrick, Jennifer S., Fan, Wenjun, Wong, Nathan D., Andrade, Katherine E., Johnson, Jonathan, Philip, Sephy, Abrahamson, David, Jiao, Lixia, Bhatt, Deepak L., Weintraub, William S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097618/
https://www.ncbi.nlm.nih.gov/pubmed/35574517
http://dx.doi.org/10.1016/j.ajpc.2022.100345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097618/
https://www.ncbi.nlm.nih.gov/pubmed/35574517
http://dx.doi.org/10.1016/j.ajpc.2022.100345

Ejemplares similares